Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110487 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Completed
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
NCT00110487 is a Phase 2 study that has completed, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 200 participants.
The verdict
NCT00110487, a Phase 2 study, has completed, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
Study Summary
The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ability to carry out daily activities. Qualified participants will receive no cost treatment, which may include study-related examinations, diagnostic procedures including a Pap smear, laboratory testing, and a mammogram (aged 40-45). Qualified participants will also receive study medication at no cost. As a participant, the study volunteer may also experience the satisfaction of knowing she is helping the advancement of women's health care.
Interventions
- DRUG ERB-041
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110487
The ClinicalTrials.gov registry entry for NCT00110487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ERB-041 is the first listed.
NCT00110487 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110487 about?
NCT00110487 is a clinical study titled "Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women". The purpose of this investigational study is to determine if a study medication is safe and effective in reducing the symptoms associated with endometriosis; if the study medication reduces the need for pain medication for endometriosis symptoms; and if the study medication improves a participant's ...
What is the current status of trial NCT00110487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2005-01. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00110487?
The interventions under investigation include: ERB-041 (DRUG).
Who is sponsoring clinical trial NCT00110487?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.